SCHEMBL4552580

SCHEMBL4552580

CCn1c(=O)c(-c2ccc(F)c(NC(=O)Nc3cncc(C(F)(F)F)c3)c2)cc2cnc(NC)nc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.49
RAF1 P04049 5/20 0.49
BRAF P15056 5/20 0.49
KRAS P01116 4/20 0.49
MAP2K2 P36507 2/20 0.49
MAP2K1 Q02750 2/20 0.49
SIK1 P57059 3/20 0.43
SIK2 Q9H0K1 3/20 0.43
SIK3 Q9Y2K2 3/20 0.43
KIT P10721 1/20 0.43
PDGFRA P16234 1/20 0.43
LCK P06239 2/20 0.42
JAK3 P52333 1/20 0.42
MAPK14 Q16539 1/20 0.42
GAK O14976 1/20 0.41
ABL1 P00519 1/20 0.41
EPHA1 P21709 1/20 0.41
EPHA2 P29317 1/20 0.41
EPHA3 P29320 1/20 0.41
EPHB2 P29323 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5062959 0.90 BRAF (0.51) KDRRAF1BRAFKRASMAP2K2
SCHEMBL4278031 0.86 BRAF (0.66) KDRRAF1BRAFKRASMAP2K2
SCHEMBL4270638 0.86 KDR (0.53) KDRRAF1BRAFKRASMAP2K2
SCHEMBL5057555 0.83 BRAF (0.51) KDRRAF1BRAFKRASMAP2K2
SCHEMBL5057671 0.83 SIK2 (0.53) KDRRAF1BRAFKRASMAP2K2
SCHEMBL4278999 0.81 LCK (0.53) KDRRAF1BRAFKRASMAP2K2
SCHEMBL5057372 0.81 LCK (0.55) KDRRAF1BRAFKRASSIK2
SCHEMBL4428372 0.81 KDR (0.57) KDRRAF1BRAFKRASMAP2K2
SCHEMBL5062718 0.80 BRAF (0.58) KDRRAF1BRAFKRASMAP2K2
SCHEMBL4424987 0.80 BRAF (0.56) KDRRAF1BRAFKRASMAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US claimed
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 KDR 500/4885RAF1 3/4885BRAF 1/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 KDR 500/4885RAF1 3/4885BRAF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.